A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
174
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AstraZeneca